Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity

被引：39

作者：

Clynes, Raphael

机构：

[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA

[2] Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2006年 / 20卷 / 03期

关键词：

D O I：

10.1016/j.hoc.2006.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Engineered antibody therapeutics have provided new treatment options in cancer. Genetic evidence in man and in the mouse suggests that Fc receptor (FcR) engagement contributes mechanistically to the therapeutic activity of naked antibodies. Preferential activation of activating FcRs and limited engagement of inhibitory FcRs enhance tumor responses in mouse models. Thus, engineered Fc domains with favorable affinities for specific FcR types may prove to be clinically superior. © 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：585 / 612

页数：28

相关论文

共 134 条

[11] FcγRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis [J].

Clatworthy, MR ;

Smith, KGC .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (05) :717-723

[12] Fc receptors are required in passive and active immunity to melanoma [J].

Clynes, R ;

Takechi, Y ;

Moroi, Y ;

Houghton, A ;

Ravetch, JV .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :652-656

[13] Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis [J].

Clynes, R ;

Dumitru, C ;

Ravetch, JV .

SCIENCE, 1998, 279 (5353) :1052-1054

[14] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[15] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[16] Rituximab in the treatment of diffuse large B-Cell lymphomas [J].

Coiffier, B .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :30-35

[17] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[18] Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents [J].

Cragg, MS ;

Glennie, MJ .

BLOOD, 2004, 103 (07) :2738-2743

[19] Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts [J].

Cragg, MS ;

Morgan, SM ;

Chan, HTC ;

Morgan, BP ;

Filatov, AV ;

Johnson, PWM ;

French, RR ;

Glennie, MJ .

BLOOD, 2003, 101 (03) :1045-1052

[20]

Czuczman MS, 1999, SEMIN ONCOL, V26, P88

← 1 2 3 4 5 6 7 8 9 10 →